Abstract S-(+)-Norfenfluramine (SNF)—an active metabolite of the now-banned anorexigen fenfluramine—has been implicated in the drug's appetite-suppressing actions and its life- threatening cardiovascular side effects. SNF reduces appetite through serotonin 5-HT 2C receptor activation; it causes cardiopulmonary side effects through 5-HT 2B receptor activation. Thus, we attempted to identify molecular determinants of SNF binding to 5-HT ...
[Groutas, W. C.; Brubaker, M. J.; Zandler, M. E.; Mazo-Gray, V.; Rude, S. A.; et al. Journal of Medicinal Chemistry, 1986 , vol. 29, # 7 p. 1302 - 1305]